Trade Mark Journal No.2026/026 26 June 2026
WO0000001914745 (1,5,35,42)
Office of origin: Switzerland
Date of International Registration:15 December 2025
Date of designation in the UK:
15 December 2025
International priority date claimed: 16 June 2025
(Switzerland)
(834414)
- Class 1
- Peptides, peptide derivatives, proteins, glycans, lipids, active principle antibody conjugates, antibody fragments, antibody derivatives, vectors for scientific use; chemical, biological, biotechnological and molecular genetic preparations, namely polypeptides and proteins for reagent development or production for industrial and scientific applications; biological preparations, namely, polypeptides, peptide derivatives for laboratories and analysis for industrial and scientific applications; chemical and biochemical substances for manufacturing pharmaceutical products.
- Class 5
- Pharmaceutical products and medical preparations in the field of cancer therapy; biopharmaceuticals and medical preparations in the field of active antibody conjugates; chemical, biological, molecular and biochemical genetic and biopharmaceutical products for medical and pharmaceutical use, namely peptides, peptide derivatives, active principle antibody conjugates, antibody fragments, antibody derivatives, vectors; pharmaceutical products and substances for disease treatment and preparations for medical treatments.
- Class 35
- Provision of information with respect to business contacts for research projects.
- Class 42
- Scientific, medical, biological, molecular genetic, chemical, pharmaceutical and technological research, in the field of biochemistry or pharmacy; biochemical or pharmaceutical laboratory services; industrial analysis and research services; development and experimentation of medicines; conducting preclinical and clinical trials; laboratory services for the benefit of third parties; scientific advisory services in the biochemical, biological and molecular genetic fields; scientific advice for the pharmaceutical industry sector; analysis services for medical and pharmaceutical research services in connection with the treatment of individuals, included in class 42; provision of scientific research information and results.
Araris Biotech AG
Representative: Fox Williams LLP, 10 Finsbury Square London EC2A 1AF UNITED KINGDOM